USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
INTEGRATED BIOTHERAPEUTICS, INC.
Address:
Gaithersburg, MD
Phone:
(301) 360-3505
URL:
N/A
EIN:
120305284
DUNS:
601000750
Number of Employees:
16
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,146,443.00 9
SBIR Phase II $429,456.00 1
STTR Phase I $600,000.00 1

Award List:

ANTI-ID ANTIBODY VACCINE FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$43,256.00
Agency:
HHS
Principal Investigator:
John H Slack
Abstract:
Respiratory syncytial virus (rsv) is now recognized as the leading cause of hospitalization of children during the first year of life as well as the leading cause of pediatric noscomial infection. the infection carries an association mortality rate of 0.5%, and recent estimated by th institute of… More

Anti-Id Vaccine for the Prevention of Endotoxemia

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Brian D. Reynolds
Abstract:
The hemodynamic collapse of septic shock is the leading cause of death in critically ill patients and is the thirteenth leading cause of death overall in the United States; septic shock accounts for annual medical expenses approaching ten billion dollars. The bacterial component widely believed to… More

THE DEVELOPMENT OF MOLECULARLY PURE ANTIBODY REAGENTS TO VARIANT STRAINS OF MEASLES VIRUS

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,432.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$69,247.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
M. J. Aman, President & Chief Scientific Office
Abstract:
Research Proposed: Determine the feasibility of developing human hyperimmune serum (HIS) against staphylococcal enterotoxin B (SEB). PROBLEM/OPPORTUNITY: Staphylococcus aureus is associated with up to 25% of invasive infections in hospitals and community. Staphylococcal exotoxins (SEs), including… More

Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$429,456.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
M. J. Aman, President and CSO
Abstract:
This Phase II SBIR project addresses the need to develop a treatment for toxic shock induced by staphylococcal Enterotoxin B (SEB), which may be disseminated as an aerosol in a biowarfare scenario. Specifically, we seek to develop a hyperimmune human polyclonal antibody that neutralizes the toxic… More

Development of a Panton Valentine Leukocidin bivalent vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus aureus (S.aureus) is a formidable human pathogen responsible for severe infections in the hospitals and community. S. aureus produces a variety of virulence factors including a range of exotoxins with imm une inhibitory, immunomodulatory, and… More

Development of a novel second-generation pan-filovirus subunit vaccine

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Kelly L. Warfield – 240-454-8936
Abstract:
DESCRIPTION (provided by applicant): Filoviruses, Ebola and Marburg, are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, designated as category A select agents by the Centers for Disease Control and Prevention, are considered potential… More

Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$550,414.00
Agency:
HHS
Principal Investigator:
Sven G. Enterlein – 240-778-6555
Abstract:
DESCRIPTION (provided by applicant): Filoviruses, Ebola (EBOV) and Marburg (MARV), are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, designated as category A select agents by the Centers for Disease Control and Prevention, are considered… More

A novel Structure Based Vaccine for staphylococcal alpha hemolysin

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$590,778.00
Agency:
HHS
Principal Investigator:
Rajan P. Adhikari – 240-454-8935
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus aureus is a gram positive human pathogen that causes a wide range of infections ranging from skin and soft tissue infections to life threatening diseases like sepsis and pneumonia. S. aureus is well knownfor its ability to acquire and evolve… More

Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$593,316.00
Agency:
HHS
Principal Investigator:
M. J. Aman – 240-454-8940
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus aureus is a human pathogen that causes a wide range of diseases from skin and soft tissue infections (SSTI) to life threatening sepsis and pneumonia. Infections with S. aureus in the hospitals and community have been on the rise over the past two… More

Immunotherapeutics to prevent HCV reinfection

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Kelly L. Warfield – 240-454-8936
Research Institution:
STANFORD UNIVERISTY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of… More